In adults with Prader–Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels by Purtell, L et al.
L.	  Purtell	  et	  al.:	  	  
Neuropeptides	  45(4):	  301-­‐307,	  2011	  
In adults with Prader–Willi syndrome, elevated ghrelin levels 
are more consistent with hyperphagia than high PYY and 
GLP-1 levels 
 
Louise Purtell a,, Lisa Sze b, Georgina Loughnan c, Ellie Smith d, Herbert 
Herzog e, Amanda Sainsbury e,f, Katharine Steinbeck c,g, Lesley V. Campbell 
a,h, Alexander Viardot a  
a Diabetes & Obesity Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Sydney-
Darlinghurst, NSW 2010, Australia b Division of Endocrinology and Diabetes, Department of Internal Medicine, 
Kantonsspital St. Gallen, St. Gallen, Switzerland c Prader–Willi Syndrome Clinic, Metabolism & Obesity Services, 
Department of Endocrinology, Royal Prince Alfred Hospital, Sydney-Camperdown, NSW 2050, Australia d 
Department of Cytogenetics, The Children’s Hospital, Westmead Clinical School, Westmead, NSW 2145, Australia e 
Neuroscience Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Sydney-Darlinghurst, 
NSW 2010, Australia f School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia g 
Academic Department of Adolescent Medicine, University of Sydney, Sydney, NSW 2006, Australia h Department of 
Endocrinology, St. Vincent’s Hospital, 390 Victoria Street, Sydney-Darlinghurst, NSW 2010, Australia  
ABSTRACT 
Objective 
Prader–Willi syndrome (PWS) is a leading genetic cause of obesity, characterized by 
hyperphagia, endocrine and developmental disorders. It is suggested that the intense 
hyperphagia could stem, in part, from impaired gut hormone signaling. Previous studies 
produced conflicting results, being confounded by differences in body composition between 
PWS and control subjects. 
Design 
Fasting and postprandial gut hormone responses were investigated in a cross-sectional 
cohort study including 10 adult PWS, 12 obese subjects matched for percentage body fat and 
central abdominal fat, and 10 healthy normal weight subjects. 
Methods 
PYY[total], PYY[3–36], GLP-1[active] and ghrelin[total] were measured by ELISA or 
radioimmunoassay. Body composition was assessed by dual energy X-ray absorptiometry. 
Visual analog scales were used to assess hunger and satiety. 
Results 
In contrast to lean subjects (p < 0.05), PWS and obese subjects were similarly insulin 
resistant and had similar insulin levels. Ghrelin[total] levels were significantly higher in PWS 
compared to obese subjects before and during the meal (p < 0.05). PYY[3–36] meal 
responses were higher in PWS than in lean subjects (p = 0.01), but not significantly different 
to obese (p = 0.08), with an additional non-significant trend in PYY[total] levels. There were 
no significant differences in self-reported satiety between groups, however PWS subjects 
reported more hunger throughout (p = 0.003), and exhibited a markedly reduced meal-
induced suppression of hunger (p = 0.01) compared to lean or obese subjects. 
Conclusions 
Compared to adiposity-matched control subjects, hyperphagia in PWS is not related to a 
lower postprandial GLP-1 or PYY response. Elevated ghrelin levels in PWS are consistent 
with increased hunger and are unrelated to insulin levels. 
 
1. INTRODUCTION 
Prader–Willi syndrome (PWS), with an incidence of approximately 1 in 15,000, is a leading 
genetic cause of obesity, caused by a loss of expression of paternally imprinted genes on 
chromosome 15q11–q13 (Goldstone, 2004). After initial severe hypotonia and failure to thrive 
in infancy, children with PWS develop hyperphagia with weight gain, with onset at 2–6 years 
(Butler, 1990). The syndrome is also characterized by developmental defects and obesity-
related complications (Cassidy, 1997). However, it is the hyperphagia that causes one of the 
main impediments to independent living in adults with PWS. From childhood, constant 
vigilance, behavioral restraints and environmental modifications are necessary to prevent 
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morbid obesity. The underlying mechanisms behind defective appetite regulation in PWS are 
poorly understood, and as yet there is no specific treatment for hyperphagia in PWS. 
 Many gut-derived peptides have been shown to play a physiological role in the 
control of satiety and feeding (Karra and Batterham, 2010). Several recent studies have 
investigated the modulation of individual hormones in PWS, but disagreement exists as to 
which, if any, secretory hormone dysregulation contributes significantly to the hyperphagia of 
PWS. 
 Peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) are both anorexigenic 
hormones released from the L-cells of the intestine in response to nutrient intake. PYY is a 36 
amino acid peptide with high structural homology to neuropeptide Y and pancreatic 
polypeptide. Its major circulating form, PYY[3–36], exerts its anorexigenic actions through the 
centrally located Y2 receptor (Vincent and le Roux, 2008). Circulating PYY levels are 
suppressed in fasting and rise for several hours after a meal (Adrian et al., 1985 and Yang, 
2002). Infusion of PYY has been shown to decrease appetite and food intake in humans, 
leading to its being proposed as a potential obesity treatment (Degen et al., 
2005 and Chelikani et al., 2007). 
 GLP-1 has several physiological functions: GLP-1 increases insulin secretion and 
suppresses glucagon levels in a glucose-dependent manner, decreasing food intake, slowing 
gastric emptying and increasing satiety (Baggio and Drucker, 2004). Its active form (GLP-1[7–
36]) is rapidly degraded by the enzyme dipeptidyl peptidase-IV (DPP-IV) within approximately 
2 min after secretion (Drucker, 2002). 
 Both PYY and GLP-1, acting peripherally as well as in the hypothalamus, play a 
critical role in satiety and energy homeostasis. However, their role in PWS, if any, is yet to be 
established (Karra and Batterham, 2010). One study of adult males and females with PWS 
showed no difference in fasting GLP-1 levels compared to obese controls (Goldstone et al., 
2004). However, as GLP-1 is secreted in response to nutrient intake, differences may exist 
postprandially. A small number of studies have investigated postprandial PYY in PWS with 
conflicting results and there is no consensus as to whether postprandial PYY levels differ to 
those of obese controls (Butler et al., 2004, Goldstone et al., 2005, Gimenez-Palop et al., 
2007, Paik et al., 2007a and Bizzarri et al., 2010). However, results were limited due to small 
subject numbers and inadequate subject matching. 
 Some previous research in PWS has focused on ghrelin, an orexigenic peptide 
produced in the stomach and pancreas. Ghrelin levels are regulated by nutritional state; high 
in fasting, it is suppressed for several hours postprandially. It has been shown to acutely 
stimulate food intake and growth hormone release (Cummings, 2006) and its chronic 
administration causes obesity in rodents (Wren et al., 2001). Although ghrelin levels are 
usually negatively associated with BMI, in PWS subjects ghrelin is unrelated to BMI (Haqq et 
al., 2003). This and several other studies have consistently demonstrated markedly elevated 
fasting ghrelin in PWS children and adults, and it has been proposed that ghrelin 
hypersecretion may be implicated in hyperphagia and delayed meal termination in PWS 
(DelParigi et al., 2002, Goldstone et al., 2004 and Tauber et al., 2004). 
 Adipose tissue distribution is a major predictor of metabolic state. A high ratio of 
visceral to subcutaneous fat predicts complications such as impaired glucose metabolism and 
hypertension (Matsuzawa, 2008). Despite the morbid obesity often associated with PWS, 
subjects have been reported to have a lower visceral adiposity compared to weight-matched 
controls, which is usually associated with greater insulin sensitivity (Goldstone et al., 
2001 and Goldstone et al., 2004). Differences in fat distribution can influence hormone levels, 
so inadequate adiposity matching in past studies might have hampered understanding of the 
role of appetite regulating hormones in PWS. 
 A clear understanding of the mechanisms behind abnormal appetite regulation in 
PWS is necessary for the development and implementation of therapeutic strategies. While 
no clear understanding exists and reports are contradictory, this study is the first to assess 
the postprandial PYY, GLP-1 and ghrelin profiles in PWS independently of adiposity and fat 
distribution, and assess their contribution to expressed hunger and satiety during a solid 
standard meal. 
 
2. SUBJECTS AND METHODS 
 
2.1. Subjects 
This study was approved by the St. Vincent’s and Royal Prince Alfred Hospital’s Human 
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Research Ethics Committee. Written informed consent was obtained from participants’ 
parents or guardians. PWS subjects were recruited from the specialized New South Wales 
Prader–Willi Syndrome Clinic at the Royal Prince Alfred Hospital, Camperdown NSW, 
Australia. Lean and obese control subjects were recruited by public advertisement. The PWS 
group consisted of 10 subjects with a typical PWS phenotype (6 males and 4 females, aged 
27.9 (2.7) years, BMI 37.0 (2.9) kg/m2 (mean (SEM)). Each PWS subject had diagnosis 
confirmed by cytogenetic testing (5 deletions, 5 uniparental disomy). Hyperphagia was 
assessed by the 13-point hyperphagia questionnaire by Dykens et al. (2007), and mean 
behavior, drive and severity scores were as reported in the corresponding age range in PWS. 
The obese control group consisted of 12 subjects (7 males and 5 females, aged 31.9 
(2.5) years, BMI 34.3 (1.2) kg/m2) matched for age, gender and BMI with the PWS group. The 
lean control group consisted of 10 gender- and age-matched subjects (5 males and 5 
females, aged 28.8 (1.1) years, BMI 21.4 (0.4) kg/m2). Because of the heterogeneity of the 
PWS cohort, matching was conducted by recruiting control groups with similar gender, age 
and BMI, rather than by individual case matching. Three PWS subjects had type 2 diabetes 
(T2D) (treated with metformin alone, metformin and gliclazide, and metformin and Mixtard 
30/70, mean HbA1c 7.3%). Similarly, two obese control subjects had T2D (treated with 
metformin and gliclazide, and metformin, sitagliptin and rosiglitazone, mean HbA1c 7.6%). 
Three PWS subjects and 1 obese control subject had diagnosed obstructive sleep apnoea 
syndrome. Three PWS and 2 obese control subjects were treated with statins, and 1 PWS 
and 1 obese control subject were treated with aspirin 300 mg/day. Four PWS subjects took 
psychotropic medication, including anticonvulsants and antidepressants, whereas 2 obese 
control subjects took antidepressants. Five of 6 male PWS subjects were treated with low 
dose testosterone, whereas 1 of 4 PWS females took hormone replacement therapy. No 
PWS subjects had received growth hormone. All lean control subjects were healthy non-
smokers taking no medication. Subjects were excluded from this study if they had acute 
infection, were taking appetite reducing agents or had recently undergone rapid weight loss. 
 
2.2. Study design 
All subjects fasted for 10 h before presenting at the Garvan Institute Clinical Research Facility 
at 0800 h. All PWS subjects were supervised by parents or carers to ensure that the fasting 
instructions were followed. Weight and height after voiding were measured using a wall-
mounted stadiometer and electronic scale (TANITA, Wedderburn) in a hospital gown. Body 
mass index (BMI) was calculated by dividing weight (in kg) by height (in meters) squared 
(kg/m2). Waist circumference was measured as the narrowest distance between the lower 
end of the ribs and the anterior superior iliac spines, and hip circumference as the widest 
circumference between the anterior superior iliac spines and the greater trochanters. Brachial 
blood pressure was measured by an Automatic Oscillometric Digital Blood Pressure Monitor 
(OMRON HEM-705CP, OMRON Corp., Tokyo, Japan). Two measurements were taken under 
standardized conditions, the subject sitting at approximately 45° in bed. An IV cannula was 
inserted into the antecubital vein and fasting blood samples were obtained before subjects 
consumed a standardized breakfast of mixed high carbohydrate and high fat content 
(600 kcal, 50% carbohydrate, 35% fat, 15% protein) within 20 min. The study meal was 
specifically designed to be similar to a usual breakfast for PWS subjects, all subjects finishing 
eating in <20 min. Additional blood samples were collected 15, 30, 45, 60, 90, 120, 180 and 
240 min after meal commencement for measurement of glucose and hormones as described 
below. Serum and plasma samples were stored at −80 °C until assayed. 
 
2.3. Body composition 
Whole body dual energy X-ray absorptiometry (DXA) (Lunar DPX GE-Lunar, Lunar Corp., 
Madison, WI) was used to analyze body composition. As previously described (Carey et al., 
1996), a central abdominal window was outlined manually extending from the upper border of 
L2 to the lower border of L4 and laterally to the outer margin of the rib cage. The fat in this 
window was measured and expressed as mass (central abdominal fat in kilograms) and as 
percentage of the total soft tissue content in this area. Although this window contains both 
intra-abdominal fat and subcutaneous abdominal fat, it excludes 30% of the latter, has a 
relatively high intra-abdominal and low subcutaneous abdominal fat content, and has been 
shown to be strongly inversely related to insulin sensitivity assessed by the euglycemic-
hyperinsulinemic clamp. Our group has previously demonstrated a CV of less than 6% for 
central abdominal fat, based on data from 10 female subjects scanned on four separate 
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occasions (Carey et al., 1996). Central abdominal fat mass measured by DXA correlates 
highly with visceral fat mass measured by other methods such as MRI and CT, and has been 
validated previously (Park et al., 2002 and Stewart et al., 2003). 
 
2.4. Assessment of hunger and satiety 
To achieve most reliable ratings of hunger and satiety before and after the test meal, we 
adapted visual analog scales (VAS) specifically for the capabilities of PWS patients. It is 
difficult to know if PWS adults really are able to distinguish between hunger and satiety, 
therefore, we chose two questions from the commonly used questionnaire by Hill and Blundell 
(1982), “how much could you eat now?” to assess hunger and “how full do you feel” to assess 
satiety. Pre-tests at the PWS clinics showed that PWS subjects (n = 10) had difficulties rating 
their feelings on a merely numeric scale, and their answers were often influenced by the 
ample explanations by investigators and carers. This was avoided by enhancing the appetite 
VAS with simple pictures of increasing amounts of the meal above the numeric scale. Satiety 
was assessed according to Shapira et al. (2004), where the VAS was enhanced with cartoons 
of increasingly protruding bellies above the numeric scale (Supplementary Fig. 1). 
 
2.5. Biochemical measures 
Glucose was measured immediately in whole blood by the glucose oxidase method YSI 
glucose analyzer (model 2300 STAT PLUS 230V, YSI, Inc., Yellow Springs, OH, USA). 
Serum insulin and plasma PYY[total], PYY[3–36] and ghrelin(total) were measured by 
radioimmunoassay with commercially available kits (LINCO Research, Inc., St. Charles, 
USA). The sensitivity of the insulin assay was 2 µU/mL. Inter- and intra-assay coefficients of 
variation (CVs) were <5%. The sensitivity of the PYY[total] assay was 10 pg/mL, specificity 
was 100% for human PYY[1–36], PYY[3–36], [Pro34]PYY and [Leu31, Pro34]PYY and <0.1% 
for human pancreatic polypeptide and neuropeptide Y. Inter- and intra-assay CVs were 
<3.5%. The sensitivity of the PYY[3–36] assay was 20 pg/mL, specificity was 100% for 
PYY[3–36] and not detectable up to 1000 pg/mL for PYY[1–36]. Inter- and intra-assay CVs 
were <8.5%. The sensitivity of the ghrelin[total] assay was 93 pg/mL, specificity was 100% for 
human ghrelin, ghrelin 14–28 and des-octanoylghrelin. Inter- and intra-assay CVs were <4%. 
 GLP-1[active] was measured in plasma by enzyme-linked immunosorbent assay 
(LINCO Research, Inc., St. Charles, USA). For PYY and GLP-1[active] measurements, 
500 KIU/mL Aprotinin (Sigma, Sydney, Australia) and 10 µL/mL DPP-IV inhibitor (LINCO 
Research, Inc., St. Charles, USA) were added to EDTA blood collection tubes before blood 
samples were taken to prevent proteolysis. The sensitivity of the GLP-1 assay was 2 pM, 
specificity was 100% for GLP-1[7–36 amide] and GLP-1[7–37] and not detectable for GLP-
1[9–36 amide], GLP-2 and glucagon. Inter- and intra-assay coefficients of variation (CVs) 
were <8%. 
 HOMA-IR and HOMA-β were used to estimate insulin resistance and beta-cell 
function, respectively, as described previously (Matthews et al., 1985). 
 
2.6. Statistical analysis 
Results are expressed as mean (SEM). Meal responses were calculated as average 
postprandial values obtained from areas under the curves (AUC, 0–240 min) using the 
trapezoidal rule, divided by time. Analyses were performed using JMP 8.0 (SAS Institute Inc.). 
All hormone data were Ln-transformed for analysis. Differences in subject characteristics 
between the PWS group and obese and lean controls were assessed using Dunnett’s test. 
Two-way repeated measures ANOVA was used to assess differences in baseline and meal 
responses between groups, with repeats in time (baseline, average postprandial) and 
planned contrasts between PWS and obese controls and PWS and lean controls; residuals 
from all models were normally distributed (p > 0.05, Shapiro–Wilk W test). P < 0.05 was 
considered significant. 
 
3. RESULTS 
3.1. Clinical parameters 
Characteristics of all subjects are summarized in Table 1. Groups were matched for gender 
and age. PWS and obese subjects were matched for BMI with similar total body and 
abdominal fat. HOMA-IR and HOMA-B, estimates of insulin resistance and beta-cell function 
respectively, were similarly elevated in PWS and obese subjects compared to lean controls. 
Height and lean body mass, intrinsic features of the syndrome, were significantly lower in 
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PWS than obese subjects. PWS lean mass was similar to lean control subjects. 
 
 
 
3.2. Hunger and satiety 
Feelings of hunger and satiety were regularly assessed using a visual analog scale in the 
fasting state and during the meal. While suppression of hunger after the meal was similar in 
obese and lean subjects, it was absent in PWS (Table 2, Fig. 1A). However, there was no 
difference in reported satiety between groups (Fig. 1B). 
 
 
 
 
3.3. Glucose and insulin levels 
Fasting glucose levels were not different between groups (Table 2). However, the 
postprandial rise in plasma glucose (expressed as area under the curve (AUC) divided by 
time) was higher in PWS (6.2 (0.5) mmol/L) compared to obese (5.6 (0.3) mmol/L, p = 0.04) 
and lean controls (5.0 (0.1) mmol/L, p = 0.04) (Table 2, Fig. 2A). 
 
fat, 15% protein) within 20 min. The study meal was specifically
designed to be similar to a usual breakfast for PWS subjects, all
subjects finishing eating in <20 min. Additional blood samples
were collected 15, 30, 45, 60, 90, 120, 180 and 240 min after meal
commencement for measurement of glucose and hormones as de-
scribed below. Serum and plasma samples were stored at !80 !C
until assayed.
2.3. Body composition
Whole body dual energy X-ray absorptiometry (DXA) (Lunar
DPX GE-Lunar, Lunar Corp., Madison, WI) was used to analyze body
composition. As previously described (Carey et al., 1996), a central
abdominal window was outlined manually extending from the
upper border of L2 to the lower border of L4 and laterally to the
outer margin of the rib cage. The fat in this window was measured
and expressed as mass (central abdominal fat in kilograms) and as
percentage of the total soft tissue content in this area. Although
this window contains both intra-abdominal fat and subcutaneous
abdominal fat, it excludes 30% of the latter, has a relatively high in-
tra-abdominal and low subcutaneous abdominal fat content, and
has been shown to be strongly inversely related to insulin sensitiv-
ity assessed by the euglycemic-hyperinsulinemic clamp. Our group
has previously demonstrated a CV of less than 6% for central
abdominal fat, based on data from 10 female subjects scanned on
four separate occasions (Carey et al., 1996). Central abdominal fat
mass measured by DXA correlates highly with visceral fat mass
measured by other methods such as MRI and CT, and has been val-
idated previously (Park et al., 2002; Stewart et al., 2003).
2.4. Assessment of hunger and satiety
To achieve most reliable ratings of hunger and satiety before
and after the test meal, we adapted visual analog scales (VAS) spe-
cifically for the capabilities of PWS patients. It is difficult to know if
PWS adults really are able to distinguish between hunger and sati-
ety, therefore, we chose two questions from the commonly used
questionnaire by Hill and Blundell (1982), ‘‘how much could you
eat now?’’ to assess hunger and ‘‘how full do you feel’’ to assess
satiety. Pre-tests at the PWS clinics showed that PWS subjects
(n = 10) had difficulties rating their feelings on a merely numeric
scale, and their answers were often influenced by the ample expla-
nations by investigators and carers. This was avoided by enhancing
the appetite VAS with simple pictures of increasing amounts of the
meal above the numeric scale. Satiety was assessed according to
Shapira et al. (2004), where the VAS was enhanced with cartoons
of increasingly protruding bellies above the numeric scale
(Supplementary Fig. 1).
2.5. Biochemical measures
Glucose was measured immediately in whole blood by the glu-
cose oxidase method YSI glucose analyzer (model 2300 STAT PLUS
230V, YSI, Inc., Yellow Springs, OH, USA). Serum insulin and plasma
PYY[total], PYY[3–36] and ghrelin(total) were measured by radio-
immunoassay with commercially available kits (LINCO Research,
Inc., St. Charles, USA). The sensitivity of the insulin assay was
2 lU/mL. Inter- and intra-assay coefficients of variation (CVs) were
<5%. The sensitivity of the PYY[total] assay was 10 pg/mL, specific-
ity was 100% for human PYY[1–36], PYY[3–36], [Pro34]PYY and
[Leu31, Pro34]PYY and <0.1% for human pancreatic polypeptide
and neuropeptide Y. Inter- and intra-assay CVs were <3.5%. The
sensitivity of the PYY[3–36] assay was 20 pg/mL, specificity was
100% for PYY[3–36] and not detectable up to 1000 pg/mL for
PYY[1–36]. Inter- and intra-assay CVs were <8.5%. The sensitivity
of the ghrelin[total] assay was 93 pg/mL, specificity was 100% for
human ghrelin, ghrelin 14–28 and des-octanoylghrelin. Inter-
and intra-assay CVs were <4%.
GLP-1[active] was measured in plasma by enzyme-linked
immunosorbent assay (LINCO Research, Inc., St. Charles, USA). For
PYY and GLP-1[active] measurements, 500 KIU/mL Aprotinin (Sig-
ma, Sydney, Australia) and 10 lL/mL DPP-IV inhibitor (LINCO
Research, Inc., St. Charles, USA) were added to EDTA blood collec-
tion tubes before blood samples were taken to prevent proteolysis.
The sensitivity of the GLP-1 assay was 2 pM, specificity was 100%
for GLP-1[7–36 amide] and GLP-1[7–37] and not detectable for
GLP-1[9–36 amide], GLP-2 and glucagon. Inter- and intra-assay
coefficients of variation (CVs) were <8%.
HOMA-IR and HOMA-bwere used to estimate insulin resistance
and beta-cell function, respectively, as described previously (Mat-
thews et al., 1985).
2.6. Statistical analysis
Results are expressed as mean (SEM). Meal responses were cal-
culated as average postprandial values obtained from areas under
the curves (AUC, 0–240 min) using the trapezoidal rule, divided
by time. Analyses were performed using JMP 8.0 (SAS Institute
Inc.). All hormone data were Ln-transformed for analysis. Differ-
ences in subject characteristics between the PWS group and obese
and lean controls were assessed using Dunnett’s test. Two-way re-
peated measures ANOVA was used to assess differences in baseline
and meal responses between groups, with repeats in time (base-
line, average postprandial) and planned contrasts between PWS
and obese controls and PWS and lean controls; residuals from all
models were normally distributed (p > 0.05, Shapiro–Wilk W test).
P < 0.05 was considered significant.
3. Results
3.1. Clinical parameters
Characteristics of all subjects are summarized in Table 1.
Groups were matched for gender and age. PWS and obese subjects
were matched for BMI with similar total body and abdominal fat.
HOMA-IR and HOMA-B, estimates of insulin resistance and beta-
cell function respectively, were similarly elevated in PWS and ob-
ese subjects compared to lean controls. Height and lean body mass,
intrinsic features of the syndrome, were significantly lower in PWS
Table 1
Anthropometric measures of PWS, obese and lean subjects.
Variables PWS Obese Lean
n (m/f) 10 (6/4) 12 (7/5) 10 (5/5)
Age (years) 27.9 (2.7) 31.9 (2.5) 28.8 (1.1)
Height (cm) 154.9 (4.0) 167.8 (2.1)* 168.7 (2.9)*
Weight (kg) 88.0 (7.1) 95.9 (2.2) 60.9 (2.2)*
BMI (kg/m2) 37.0 (2.9) 34.3 (1.2) 21.4 (0.4)*
Waist (cm) 112.1 (5.8) 106.3 (2.4) 72.7 (1.3)*
WHR 0.93 (0.02) 0.90 (0.02) 0.79 (0.02)*
Whole body fat mass (kg) 42.6 (5.3) 40.3 (3.4) 14.6 (1.7)*
Whole body fat mass (%) 49.0 (2.5) 41.8 (2.9) 24.3 (2.9)*
Whole body lean mass (kg) 47.3 (2.7) 52.7 (2.6)* 43.7 (2.7)
Whole body lean mass (%) 49.9 (2.7) 55.2 (2.9) 71.5 (2.9)*
Abdominal fat mass (kg) 3.0 (0.4) 3.4 (0.3) 1.0 (0.1)*
Abdominal fat mass (%) 46.3 (2.4) 46.3 (2.2) 24.8 (2.2)*
HOMA-IR 3.4 (0.6) 3.4 (0.4) 1.7 (0.1)*
HOMA-B 60.8 (8.2) 60.2 (6.2) 35.5 (3.1)*
Data expressed as mean (SEM).
HOMA, homeostasis model assessment for insulin resistance (-IR) or beta-cell
function (-B); WHR, waist-to-hip ratio.
* Significantly different to PWS group (p<0.05, Dunnett’s test).
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than obese subjects. PWS lean mass was similar to lean control
subjects.
3.2. Hunger and satiety
Feelings of hunger and satiety were regularly assessed usi g a
visual analog scale in the fasting state and during the meal. While
suppression of hunger after the meal was similar in obese and lean
subjects, it was absent in PWS (Table 2, Fig. 1A). However, there
was no difference in reported satiety between groups (Fig. 1B).
3.3. Glucose and insulin levels
Fasting glucose levels were not different between groups (Table
2). However, the postprandial rise in plasma glucose (expressed as
area under the curve (AUC) divided by time) was higher in PWS
(6.2 (0.5) mmol/L) compared to obese (5.6 (0.3) mmol/L, p = 0.04)
and lean controls (5.0 (0.1) mmol/L, p = 0.04) (Table 2, Fig. 2A).
Fasting insulin levels were similarly elevated in PWS (16.0
(2.7) lU/ml) an obese subjects (15.1 (1.5) lU/ml) compared to
lean subjects (7.8 (0.6) lU/ml, p = 0.005) (Table 2).
The postprandial insulin response tended to be higher in PWS
(51 (12) lU/ml) and obese subjects (43 (5) lU/ml) compared to
lean controls (26 (3) lU/ml, p = n.s.), without statistical signifi-
cance (Table 2, Fig. 2B).
3.4. Anorexigenic hormones PYY and GLP-1
PWS, obese and lean subjects all had similar fasting levels of
PYY[total], PYY[3–36] and GLP-1[active] (Table 2). The postpran-
dial response of PYY[total] tended to be higher in PWS than obese
subjects (75 (7) vs. 71 (12) pg/ml, p = 0.08), without statistical sig-
nificance (Fig. 2C). The postprandial PYY[3–36] response was sig-
nificantly higher in PWS vs. lean subjects (59 (5) vs. 53 (4) pg/ml,
p = 0.02), and tended to be higher than in obese controls (54 (8),
p = 0.08) (Fig. 2D). The postprandial meal response of GLP-1[active]
was not statistically different between groups (Fig. 2E).
3.5. Orexigenic hormone ghreli
Subjects with PWS had significantly higher fasting and post-
prandial ghrelin levels than obese subjects (fasting levels 1071
(170) vs. 632 (48) pg/ml, p = 0.04) (Table 2, Fig. 2F). PWS subjects
demonstrated similar postprandial ghrelin suppression to lean
subjects (!15.1 (2.2)% vs. !13.2 (3.5)%, p = n.s.), but levels re-
mained well above those of lean and obese subjects. Conversely,
ghrelin suppression in obese subjects tended to be lower compared
to PWS subjects (!6.4 (3.7)% vs. !15.1 (2.2)%, p = 0.048).
4. Discussion
Our results show that, independent of total and central adipos-
ity, as well as gender, age and BMI, the postprandial response of
PYY and GLP-1 in PWS subjects was not lower than controls.
Importantly, the meal response of PYY[3–36] was higher in PWS
compared to lean subjects. Despite high levels of satiety-inducing
hormones and self-reported feelings of satiety, significantly greater
hunger persisted in PWS subjects. This may relate to the signifi-
cantly higher levels of ghrelin observed in PWS relative to obese
controls, even when matched for adiposity, which is known to
influence circulating ghrelin levels.
It has been reported that PWS, compared to BMI matched con-
trols, had lower visceral adiposity, with a lower ratio of visceral to
subcutaneous adipose tissue (Goldstone et al., 2001; Sode-Carlsen
et al., 2010). The authors also noted that visceral fat predicted
insulin, glucose, C-peptide, triglycerides and high-density and
low-density lipoprotein cholesterol, while subcutaneous fat had
no effect on these parameters (Goldstone et al., 2001). This high-
lights the importance of controlling for differential fat deposition
as a possible cause of differences detected in hormone profiles.
The present study was able to avoid potential confounding factors
because of the similar levels of total adiposity, in addition to
matching for age, gender and BMI. Interestingly, the two groups
were also matched for central adiposity and insulin resistance
without specific selection of control subjects. Although our PWS
cohort might seem unusual, as a lower visceral fat mass and pre-
served insulin sensitivity has been reported previously (Brambilla
et al., 1997; Goldstone et al., 2001, 2004, 2005; Talebizadeh and
Butler, 2005; Kennedy et al., 2006; Theodoro et al., 2006; Haqq
et al., 2010; Sode-Carlsen et al., 2010), other investigators recently
reported similar observations to ours, i.e. obese children and adults
with PWS having the same amount of visceral fat mass, the same
degree of insulin resistance and a similar prevalence of metabolic
syndrome compared to carefully weight-matched obese subjects
Table 2
Fasting and postprandial hormone levels and VAS scores.
PWS Obese Lean p (Repeated measures ANOVA)
Group Meal Group "Meal
Glucose (mmol/l) Baseline 4.7 (0.2) 4.8 (0.3) 4.4 (0.1) 0.16 0.0001 0.04 a,b
Meal 6.2 (0.5) 5.6 (0.3) 5.0 (0.1)
Insulin (lU/ml) Baseline 16.0 (2.7) 15.1 (1.5) 7.8 (0.6) 0.005 b 0.0001 0.6
Meal 51 (12) 43 (5) 26 (3)
PYY[total] (pg/ml) Baseline 75 (7) 71 (12) 70 (5) 0.26 0.0001 0.08
Meal 116 (8) 92 (13) 87 (4)
PYY[3–36] (pg/ml) Baseline 43 (5) 46 (7) 47 (5) 0.86 0.0001 0.02 b
Meal 59 (5) 54 (8) 53 (4)
GLP-1[active] (pmol/L) Baseline 5.9 (0.6) 6.0 (0.4) 6.0 (1.0) 0.6 0.001 0.3
Meal 9.1 (1.5) 6.9 (0.6) 8.5 (2.0)
Ghrelin[total] (pg/ml) Baseline 1071 (170) 632 (48) 831 (86) 0.04a 0.0001 0.2
Meal 904 (142) 592 (50) 725 (83)
Fullness (VAS score) Baseline 1.2 (0.5) 0.8 (0.3) 0.3 (0.2) 0.75 0.0001 0.14
Meal 2.9 (0.4) 3.3 (0.5) 3.1 (0.4)
Hunger (VAS score) Baseline 6.0 (0.6) 5.3 (0.6) 4.1 (0.6) 0.003 a,b 0.0001 0.01 a,b
Meal 5.8 (0.6) 3.0 (0.4) 2.3 (0.4)
Data expressed as mean (SEM).
Meal = average calculated as AUC/time.
a PWS vs. Obese p < 0.05, contrasts within ANOVA effects.
b PWS vs. Lean p < 0.05, contrasts within ANOVA effects.
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Fasting insulin levels were similarly elevated in PWS (16.0 (2.7) µU/ml) and obese subjects 
(15.1 (1.5) µU/ml) compared to lean subjects (7.8 (0.6) µU/ml, p = 0.005) (Table 2). 
 The postprandial insulin response tended to be higher in PWS (51 (12) µU/ml) and 
obese subjects (43 (5) µU/ml) compared to lean controls (26 (3) µU/ml, p = n.s.), without 
statistical significance (Table 2, Fig. 2B). 
 
3.4. Anorexigenic hormones PYY and GLP-1 
PWS, obese and lean subjects all had similar fasting levels of PYY[total], PYY[3–36] and 
GLP-1[active] (Table 2). The postprandial response of PYY[total] tended to be higher in PWS 
than obese subjects (75 (7) vs. 71 (12) pg/ml, p = 0.08), without statistical significance (Fig. 
2C). The postprandial PYY[3–36] response was significantly higher in PWS vs. lean subjects 
(59 (5) vs. 53 (4) pg/ml, p = 0.02), and tended to be higher than in obese controls (54 (8), 
p = 0.08) (Fig. 2D). The postprandial meal response of GLP-1[active] was not statistically 
(Talebizadeh and Butler, 2005; Brambilla et al., 2010). The present
study was not designed to compare body composition and fat
distribution between PWS and obese subjects, as a larger cohort
would be needed to that end. However, the fact that PWS and ob-
ese controls had similar central and total adiposity provided an
opportunity to examine gut hormone levels independent of a ma-
jor confounding factor, helping to understand the underlying path-
ophysiology of appetite dysregulation in PWS.
Several reports have described the role of PYY in PWS, but with
conflicting results. Some have found that adults and children with
PWS have lower fasting and postprandial PYY levels than controls
(Butler et al., 2004; Gimenez-Palop et al., 2007), while others re-
ported no difference (Goldstone et al., 2005; Paik et al., 2007a) or
increased PYY levels (Bizzarri et al., 2010).
A 2004 study (Goldstone et al., 2004) assessed fasting plasma
GLP-1[total] in 12 female and 16 male adults with PWS, and found
Fig. 1. Visual analog scores (VAS) during the test meal (600 kcal) assessing hunger (A, ‘how much could you eat now?’) and satiety (B, ‘how full does your belly feel?’) in PWS
(solid line), obese (dashed line) and lean subjects (dotted line). Data are presented as mean (SEM).
Fig. 2. Glucose (A), insulin (B), PYY[total] (C), PYY[3–36] (D), GLP-1[active] (E) and ghrelin[total] (F) levels during the meal test in PWS (solid line), obese (dashed line) and
lean subjects (dotted line). Data are presented as mean (SEM).
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different between groups (Fig. 2E). 
 
3.5. Orexigenic hormone ghrelin 
Subjects with PWS had significantly higher fasting and postprandial ghrelin levels than obese 
subjects (fasting levels 1071 (170) vs. 632 (48) pg/ml, p = 0.04) (Table 2, Fig. 2F). PWS 
subjects demonstrated similar postprandial ghrelin suppression to lean subjects (−15.1 (2.2)% 
vs. −13.2 (3.5)%, p = n.s.), but levels remained well above those of lean and obese subjects. 
Conversely, ghrelin suppression in obese subjects tended to be lower compared to PWS 
subjects (−6.4 (3.7)% vs. −15.1 (2.2)%, p = 0.048). 
 
4. DISCUSSION 
Our results show that, independent of total and central adiposity, as well as gender, age and 
BMI, the postprandial response of PYY and GLP-1 in PWS subjects was not lower than 
controls. Importantly, the meal response of PYY[3–36] was higher in PWS compared to lean 
subjects. Despite high levels of satiety-inducing hormones and self-reported feelings of 
satiety, significantly greater hunger persisted in PWS subjects. This may relate to the 
significantly higher levels of ghrelin observed in PWS relative to obese controls, even when 
matched for adiposity, which is known to influence circulating ghrelin levels. 
 It has been reported that PWS, compared to BMI matched controls, had lower 
visceral adiposity, with a lower ratio of visceral to subcutaneous adipose tissue (Goldstone et 
al., 2001 and Sode-Carlsen et al., 2010). The authors also noted that visceral fat predicted 
insulin, glucose, C-peptide, triglycerides and high-density and low-density lipoprotein 
cholesterol, while subcutaneous fat had no effect on these parameters (Goldstone et al., 
2001). This highlights the importance of controlling for differential fat deposition as a possible 
cause of differences detected in hormone profiles. The present study was able to avoid 
potential confounding factors because of the similar levels of total adiposity, in addition to 
matching for age, gender and BMI. Interestingly, the two groups were also matched for 
central adiposity and insulin resistance without specific selection of control subjects. Although 
our PWS cohort might seem unusual, as a lower visceral fat mass and preserved insulin 
sensitivity has been reported previously (Brambilla et al., 1997, Goldstone et al., 2001, 
Goldstone et al., 2004, Goldstone et al., 2005, Talebizadeh and Butler, 2005, Kennedy et al., 
2006, Theodoro et al., 2006, Haqq et al., 2010 and Sode-Carlsen et al., 2010), other 
investigators recently reported similar observations to ours, i.e. obese children and adults with 
PWS having the same amount of visceral fat mass, the same degree of insulin resistance and 
a similar prevalence of metabolic syndrome compared to carefully weight-matched obese 
subjects (Talebizadeh and Butler, 2005 and Brambilla et al., 2010). The present study was 
not designed to compare body composition and fat distribution between PWS and obese 
subjects, as a larger cohort would be needed to that end. However, the fact that PWS and 
obese controls had similar central and total adiposity provided an opportunity to examine gut 
hormone levels independent of a major confounding factor, helping to understand the 
underlying pathophysiology of appetite dysregulation in PWS. 
 Several reports have described the role of PYY in PWS, but with conflicting results. 
Some have found that adults and children with PWS have lower fasting and postprandial PYY 
levels than controls (Butler et al., 2004 and Gimenez-Palop et al., 2007), while others 
reported no difference (Goldstone et al., 2005 and Paik et al., 2007a) or increased PYY levels 
(Bizzarri et al., 2010). 
 A 2004 study (Goldstone et al., 2004) assessed fasting plasma GLP-1[total] in 12 
female and 16 male adults with PWS, and found no difference in levels compared to obese 
and lean controls. However, as the authors noted, there may be postprandial changes in 
secretion of GLP-1 in PWS not measured in their study. Furthermore, it may be that the level 
of the GLP-1[active] form, GLP-1[7–36], not previously measured in PWS, is physiologically 
more important than GLP-1[total]. In the present study, GLP-1[active] showed a similar 
pattern in PWS subjects as did PYY, being similarly high postprandially as in obese and lean 
control subjects. 
 We found no evidence of an impaired postprandial satiety response in the PWS 
subjects in our study. The secretion of anorexigenic hormones PYY and GLP-1 was not 
reduced compared to control subjects, nor were VAS satiety scores altered. Despite this, 
hunger scores remained significantly higher in the PWS group, with a rapid return to fasting 
levels after meal termination. Results from the current study suggest that satiety hormones 
such as PYY and GLP-1 are unlikely to cause the lack of satiety in subjects with PWS, and 
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simple pharmacological strategies involving replacement therapy with PYY or GLP-1 might 
not be effective in treating PWS hyperphagia. Indeed, a study by Zipf et al. demonstrated that 
infusion of pancreatic polypeptide, which has similar function as a satiety factor as PYY, did 
not decrease reported hunger in children with PWS (Zipf et al., 1990). However, it remains 
possible that treatment with supraphysiological doses of a GLP-1 or PYY agonist, which may 
also affect other receptors, may still be beneficial. 
 The present study confirms previous reports (DelParigi et al., 2002, Haqq et al., 2003, 
Goldstone et al., 2004 and Tauber et al., 2004) that fasting and postprandial ghrelin levels are 
significantly higher in PWS subjects compared to obese and lean subjects. However, in 
contrast to previous reports (Purnell et al., 2003, Goldstone et al., 2004, Goldstone et al., 
2005 and McLaughlin et al., 2004), our data suggest that the observed increase in ghrelin in 
PWS is not due to altered fat distribution or hypoinsulinemia because PWS and obese 
subjects were matched for total and central adiposity and showed similar insulin secretion 
and insulin resistance. Therefore, hyperghrelinemia could be a specific feature of PWS, 
possibly caused by underlying hypothalamic defects and an imbalance of vagal nerve 
activation. 
 Despite overall higher levels of ghrelin in PWS, these subjects still exhibited normal 
postprandial suppression of ghrelin in our study, consistent with results reported in 3 studies 
of children with PWS (Haqq et al., 2003, Paik et al., 2006 and Paik et al., 2007b) and another 
of adults (Gimenez-Palop et al., 2007). Future trials are needed to elucidate the role of ghrelin 
in PWS using specific ghrelin antagonists, currently in development. 
 In healthy subjects, hunger and satiety operate in balance; when one is high the other 
is low. Interestingly, our findings in the present study confirm this pattern in lean and obese 
subjects but not in PWS subjects, who concurrently reported high satiety and high hunger 
scores. We observed an apparently normal satiety response in PWS adults, namely an 
increase in postprandial VAS fullness scores accompanied by a rise in PYY and GLP-1 
concentrations and a drop in plasma ghrelin levels. However, despite this seemingly 
appropriate physiological response to a meal, PWS subjects maintained high VAS hunger 
scores, even immediately after consumption of a large meal. The simple fact that PWS 
ghrelin levels remain higher than those of controls may be sufficient to drive appetite to 
override the observed satiety response, leading to hyperphagia. 
 One limitation of this study is a certain degree of heterogeneity of the cohorts, a 
problem almost impossible to prevent when investigating a rare disease with multiple co-
morbidities and medications. In this study, all recruited PWS subjects were included 
regardless of medical treatment. Obese control subjects were selected to be similar to the 
PWS subjects regarding medications and presence of T2D. However, certain medications, 
such as metformin, sitagliptin, insulin, and psychotropic medications can potentially have an 
impact on circulating gut hormones. To minimize these possible influences, all subjects had 
their meal study prior to taking their usual medication and insulin. In this study, subjects with 
T2D had similar gut hormone levels as non-diabetic subjects, and our results were 
unchanged when excluding all subjects with T2D. 
 In conclusion, this is the first study to investigate postprandial orexigenic and 
anorexigenic gut hormones in PWS and their relationships with hunger and satiety 
independent of visceral adiposity, BMI, age and gender. While it has been postulated that 
impaired postprandial secretion of such hormones could contribute to the hyperphagia of 
PWS, only a possible role for ghrelin promoting hunger was found, without evidence for 
involvement of GLP-1 or PYY in the hyperphagia. 
 
FUNDING 
This study was funded by a research grant established by supporters and families with 
children with Prader–Willi syndrome. L.S. was the recipient of a grant for ‘prospective 
researchers’ from the Swiss National Science Foundation. H.H. and A.S. are supported by 
Fellowships from the National Health and Medical Research Council of Australia (NHMRC). 
A.V. is the recipient of a NHMRC Clinical Overseas Research Fellowship. 
 
ACKNOWLEDGMENTS 
Our thanks go to the clinical staff of the Garvan Clinical Research Facility and particularly to 
the volunteers and their families and carers who participated in the study. We also thank 
Arthur Jenkins for his input into the statistical analysis. 
 
L.	  Purtell	  et	  al.:	  	  
Neuropeptides	  45(4):	  301-­‐307,	  2011	  
REFERENCES 
 
Adrian TE, T.E.F.G., Bacarese-Hamilton, A.J., Fuessl, H.S., Polak, J.M., Bloom, S.R., 1985. Human 
distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89, 1070–1077.  
Baggio, L.L., Drucker, D.J., 2004. Glucagon-like peptide-1 and glucagon-like peptide- 2. Best Pract. 
Res. Clin. Endocrinol. Metab. 18, 531–554.  
Bizzarri, C., Rigamonti, A.E., Luce, A., Cappa, M., Cella, S.G., Berini, J., Sartorio, A., Muller, E.E., 
Salvatoni, A., 2010. Children with Prader–Willi syndrome exhibit more evident meal-induced responses 
in plasma ghrelin and peptide YY levels than obese and lean children. Eur. J. Endocrinol. 162, 499–505.  
Brambilla, P., Bosio, L., Manzoni, P., Pietrobelli, A., Beccaria, L., Chiumello, G., 1997. Peculiar body 
composition in patients with Prader–Labhart-Willi syndrome. Am. J. Clin. Nutr. 65, 1369–1374.  
Brambilla, P., Crino, A., Bedogni, G., Bosio, L., Cappa, M., Corrias, A., Delvecchio, M., Di Candia, S., 
Gargantini, L., Grechi, E., Iughetti, L., Mussa, A., Ragusa, L., Sacco, M., Salvatoni, A., Chiumello, G., 
Grugni, G., 2010. Metabolic syndrome in children with Prader–Willi syndrome: the effect of obesity. Nutr 
Metab Cardiovasc Dis.  
Butler, M.G., 1990. Prader–Willi syndrome: current understanding of cause and diagnosis. Am. J. Med. 
Genet. 35, 319–332.  
Butler, M.G., Bittel, D.C., Talebizadeh, Z., 2004. Plasma peptide YY and ghrelin levels in infants and 
children with Prader–Willi syndrome. J. Pediatr. Endocrinol. Metab. 17, 1177–1184.  
Carey, D.G., Jenkins, A.B., Campbell, L.V., Freund, J., Chisholm, D.J., 1996. Abdominal fat and insulin 
resistance in normal and overweight women: direct measurements reveal a strong relationship in 
subjects at both low and high risk of NIDDM. Diabetes 45, 633–638.  
Cassidy, S., 1997. Prader–Willi syndrome. J. Med. Genet. 34, 917–923. Chelikani, P.K., Haver, A.C., 
Reidelberger, R.D., 2007. Intermittent intraperitoneal infusion of peptide YY(3–36) reduces daily food 
intake and adiposity in obese rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R39–46.  
Cummings, D.E., 2006. Ghrelin and the short- and long-term regulation of appetite and body weight. 
Physiol. behav. 89, 71–84.  
Degen, L., Oesch, S., Casanova, M., Graf, S., Ketterer, S., Drewe, J., Beglinger, C., 2005. Effect of 
peptide YY3–36 on food intake in humans. Gastroenterology 129, 1430–1436.  
DelParigi, A., Tschop, M., Heiman, M.L., Salbe, A.D., Vozarova, B., Sell, S.M., Bunt, J.C., Tataranni, 
P.A., 2002. High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader–Willi 
syndrome. J. Clin. Endocrinol. Metab. 87, 5461– 5464.  
Drucker, D., 2002. Biological actions and therapeutic potential of the glucagon-like peptides. 
Gastroenterology 122, 531–544.  
Dykens, E.M., Maxwell, M.A., Pantino, E., Kossler, R., Roof, E., 2007. Assessment of hyperphagia in 
Prader–Willi syndrome. Obesity (Silver Spring) 15, 1816–1826.  
Gimenez-Palop, O., Gimenez-Perez, G., Mauricio, D., Gonzalez-Clemente, J.M., Potau, N., Berlanga, 
E., Trallero, R., Laferrere, B., Caixas, A., 2007. A lesser postprandial suppression of plasma ghrelin in 
Prader–Willi syndrome is associated with low fasting and a blunted postprandial PYY response. Clin. 
Endocrinol. (Oxf) 66, 198–204.  
Goldstone, A.P., 2004. Prader–Willi syndrome: advances in genetics, pathophysiology and treatment. 
Trends Endocrinol. Metab. 15, 12–20.  
Goldstone, A.P., Thomas, E.L., Brynes, A.E., Bell, J.D., Frost, G., Saeed, N., Hajnal, J.V., Howard, J.K., 
Holland, A., Bloom, S.R., 2001. Visceral adipose tissue and metabolic complications of obesity are 
reduced in Prader–Willi syndrome female adults: evidence for novel influences on body fat distribution. 
J. Clin. Endocrinol. Metab. 86, 4330–4338.  
Goldstone, A.P., Thomas, E.L., Brynes, A.E., Castroman, G., Edwards, R., Ghatei, M.A., Frost, G., 
L.	  Purtell	  et	  al.:	  	  
Neuropeptides	  45(4):	  301-­‐307,	  2011	  	  
Holland, A.J., Grossman, A.B., Korbonits, M., Bloom, S.R., Bell, J.D., 2004. Elevated fasting plasma 
ghrelin in prader–willi syndrome adults is not solely explained by their reduced visceral adiposity and 
insulin resistance. J. Clin. Endocrinol. Metab. 89, 1718–1726.  
Goldstone, A.P., Patterson, M., Kalingag, N., Ghatei, M.A., Brynes, A.E., Bloom, S.R., Grossman, A.B., 
Korbonits, M., 2005. Fasting and postprandial hyperghrelinemia in Prader–Willi syndrome is partially 
explained by hypoinsulinemia, and is not due to peptide YY3–36 deficiency or seen in hypothalamic 
obesity due to craniopharyngioma. J. Clin. Endocrinol. Metab. 90, 2681–2690.  
Haqq, A.M., Farooqi, I.S., O’Rahilly, S., Stadler, D.D., Rosenfeld, R.G., Pratt, K.L., LaFranchi, S.H., 
Purnell, J.Q., 2003. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin 
concentrations in normal children and are markedly increased in Prader–Willi syndrome. J. Clin. 
Endocrinol. Metab. 88, 174–178.  
Haqq, A.M., Muehlbauer, M.J., Newgard, C.B., Grambow, S., Freemark, M., 2010. The metabolic 
phenotype of Prader–Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body 
mass index. J. Clin. Endocrinol. Metab..  
Hill, A.J., Blundell, J.E., 1982. Nutrients and behaviour: research strategies for the investigation of taste 
characteristics, food preferences, hunger sensations and eating patterns in man. J. Psychiatric Res. 17, 
203–212.  
Karra, E., Batterham, R.L., 2010. The role of gut hormones in the regulation of body weight and energy 
homeostasis. Mol. Cell. Endocrinol. 316, 120–128.  
Kennedy, L., Bittel, D.C., Kibiryeva, N., Kalra, S.P., Torto, R., Butler, M.G., 2006. Circulating adiponectin 
levels, body composition and obesity-related variables in Prader–Willi syndrome: comparison with 
obese subjects. Int. J. Obes. (Lond) 30, 382–387.  
Matsuzawa, Y., 2008. The role of fat topology in the risk of disease. Int. J. Obes. 32, S83–S92.  
Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., 1985. 
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose 
and insulin concentrations in man. Diabetologia 28, 412–419.  
McLaughlin, T., Abbasi, F., Lamendola, C., Frayo, R.S., Cummings, D.E., 2004. Plasma ghrelin 
concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive 
controls. J. Clin. Endocrinol. Metab. 89, 1630– 1635.  
Paik, K.H., Choe, Y.H., Park, W.H., Oh, Y.J., Kim, A.H., Chu, S.H., Kim, S.W., Kwon, E.K., Han, S.J., 
Shon, W.Y., Jin, D.K., 2006. Suppression of acylated ghrelin during oral glucose tolerance test is 
correlated with whole-body insulin sensitivity in children with Prader–Willi syndrome. J. Clin. Endocrinol. 
Metab. 91, 1876– 1881.  
Paik, K.H., Jin, D.K., Lee, K.H., Armstrong, L., Lee, J.E., Oh, Y.J., Kim, S., Kwon, E.K., Choe, Y.H., 
2007a. Peptide YY, cholecystokinin, insulin and ghrelin response to meal did not change, but mean 
serum levels of insulin is reduced in children with Prader–Willi syndrome. J. Korean Med. Sci. 22, 436–
441.  
Paik, K.H., Lee, M.K., Jin, D.K., Kang, H.W., Lee, K.H., Kim, A.H., Kim, C., Lee, J.E., Oh, Y.J., Kim, S., 
Han, S.J., Kwon, E.K., Choe, Y.H., 2007b. Marked suppression of ghrelin concentration by insulin in 
Prader–willi syndrome. J. Korean Med. Sci. 22, 177–182.  
Park, Y.W., Heymsfield, S.B., Gallagher, D., 2002. Are dual-energy X-ray absorptiometry regional 
estimates associated with visceral adipose tissue mass? Int. J. Obes. Relat. Metab. Disord. 26, 978–
983.  
Purnell, J.Q., Weigle, D.S., Breen, P., Cummings, D.E., 2003. Ghrelin levels correlate with insulin levels, 
insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or 
cortisol levels in humans. J. Clin. Endocrinol. Metab. 88, 5747–5752.  
Shapira, N.A., Lessig, M.C., Lewis, M.H., Goodman, W.K., Driscoll, D.J., 2004. Effects of topiramate in 
adults with Prader–Willi syndrome. Am. J. Ment. Retard. 109, 301–309.  
L.	  Purtell	  et	  al.:	  	  
Neuropeptides	  45(4):	  301-­‐307,	  2011	  
Sode-Carlsen, R., Farholt, S., Rabben, K.F., Bollerslev, J., Schreiner, T., Jurik, A.G., Christiansen, J.S., 
Hoybye, C., 2010. Body composition, endocrine and metabolic profiles in adults with Prader–Willi 
syndrome. Growth Horm. IGF Res. 20, 179– 184.  
Stewart, K.J., DeRegis, J.R., Turner, K.L., Bacher, A.C., Sung, J., Hees, P.S., Shapiro, E.P., Tayback, 
M., Ouyang, P., 2003. Usefulness of anthropometrics and dual-energy X-ray absorptiometry for 
estimating abdominal obesity measured by magnetic resonance imaging in older men and women. J. 
cardiopulm. rehabil. 23, 109– 114.  
Talebizadeh, Z., Butler, M.G., 2005. Insulin resistance and obesity-related factors in Prader–Willi 
syndrome: comparison with obese subjects. Clin. Genet. 67, 230– 239.  
Tauber, M., Conte Auriol, F., Moulin, P., Molinas, C., Delagnes, V., Salles, J.P., 2004. Hyperghrelinemia 
is a common feature of Prader–Willi syndrome and pituitary stalk interruption: a pathophysiological 
hypothesis. Horm. Res. 62, 49–54.  
Theodoro, M.F., Talebizadeh, Z., Butler, M.G., 2006. Body composition and fatness patterns in Prader–
Willi syndrome: comparison with simple obesity. Obesity (Silver Spring) 14, 1685–1690.  
Vincent, R.P., le Roux, C.W., 2008. The satiety hormone peptide YY as a regulator of appetite. J. Clin. 
Pathol. 61, 548–552.  
Wren, A.M., Small, C.J., Abbott, C.R., Dhillo, W.S., Seal, L.J., Cohen, M.A., Batterham, R.L., Taheri, S., 
Stanley, S.A., Ghatei, M.A., Bloom, S.R., 2001. Ghrelin causes hyperphagia and obesity in rats. 
Diabetes 50, 2540–2547.  
Yang, H., 2002. Central and peripheral regulation of gastric acid secretion by peptide YY. Peptides 23, 
349–358.  
Zipf, W.B., O’Dorisio, T.M., Berntson, G.G., 1990. Short-term infusion of pancreatic polypeptide: effect 
on children with Prader–Willi syndrome. Am. J. Clin. Nutr. 51, 162–166.  
 
	  
